Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344597 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL7156149 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL8590554 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL5350100 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL7026542 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL3546297 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL3570498 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL7154349 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL6949988 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL6956183 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003002585-A1 | [4-(4-CYANOBENZOYL)PHENYL]GLYCOPYRANOSIDE DERIVATIVES, USE OF SAME AS A MEDICAMENT, PRODUCTION METHOD THEREOF AND COMPOSITIONS | LABORATOIRES FOURNIER SA (FR) | 2003-01-09 | — | — | WO | claimed |
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11680078-B2 | Anticancer compounds | GODAVARI BIOREFINERIES LTD. (IN) | 2023-06-20 | — | — | US | disclosed |
| US-20220389046-A1 | ANTICANCER COMPOUNDS | GODAVARI BIOREFINERIES LIMITED | 2022-12-08 | — | — | US | disclosed |
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SENDA BIOSCIENCES INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3891751-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-110869024-A | Multi-biological agents and methods of use thereof | 旗舰创业创新五公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20190284222-A1 | ANTICANCER COMPOUNDS | GODAVARI BIOREFINERIES LTD. (IN) | 2019-09-19 | — | — | US | disclosed |
| WO-2018226732-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| US-7291726-B2 | Process for the preparation of 2′-halo-β-L-arabinofuranosyl nucleosides | BUKWANG PHARMACEUTICALS IND CO., LTD. (KR) | 2007-11-06 | — | — | US | disclosed |
| US-20050187384-A1 | Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides | TRIANGLE PHARMACEUTICALS | 2005-08-25 | — | — | US | disclosed |
| EP-1373288-B1 | PROCESS FOR THE PREPARATION OF 2'-HALO-BETA-L-ARABINOFURANOSYL NUCLEOSIDES | GILEAD SCIENCES INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6870048-B2 | Process for the preparation of 2'-halo-β-L-arabinofuranosyl nucleosides | TRIANGLE PHARMACEUTICALS (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1373288-A1 | PROCESS FOR THE PREPARATION OF 2'-HALO-BETA-L-ARABINOFURANOSYL NUCLEOSIDES | Triangle Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030060622-A1 | Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides | BUKWANG PHARMACEUTICAL IND CO., LTD. (KR) | 2003-03-27 | — | — | US | disclosed |
| WO-2002079213-A1 | PROCESS FOR THE PREPARATION OF 2'-HALO-$G(B)-L-ARABINOFURANOSYL NUCLEOSIDES | TRIANGLE PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284222-A1 | ANTICANCER COMPOUNDS | MKI67, CCNI, API5 | PTPN1 4052/4885POLB 1690/4885GAA 1072/4885 |
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SLC10A2, SLC10A1, BCAT2 | PTPN1 1541/4885POLB 3144/4885GAA 899/4885 |
| US-20050187384-A1 | Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides | FUCA2, FUCA1, GALE | PTPN1 4803/4885POLB 511/4885GAA 351/4885 |
| US-11680078-B2 | Anticancer compounds | MKI67, CCNI, API5 | PTPN1 4052/4885POLB 1690/4885GAA 1072/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | PTPN1 4603/4885POLB 3613/4885GAA 177/4885 |
| US-20030060622-A1 | Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides | FUCA2, FUCA1, GALE | PTPN1 4817/4885POLB 455/4885GAA 412/4885 |
| US-20220389046-A1 | ANTICANCER COMPOUNDS | MKI67, CCNI, API5 | PTPN1 4052/4885POLB 1690/4885GAA 1072/4885 |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | HSPA2, HSP90AB2P, HSF1 | PTPN1 4482/4885POLB 3229/4885GAA 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.